Bristol-Myers Squibb Names José Baselga, M.D., Ph.D. to Board of Directors
March 01 2018 - 3:15PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that its
Board of Directors has elected José Baselga, M.D., Ph.D., to the
Board, effective March 1, 2018. Dr. Baselga will serve as a member
of Science & Technology Committee of the Board of
Directors.
Dr. Baselga, 58, is currently the Physician-in-Chief at Memorial
Sloan Kettering Cancer Center, one of the world’s premier cancer
institutions, where he is responsible for the management of patient
care and plays an active role in efforts to enhance and expand
programs in clinical and translational research. He is also a
Professor of Medicine at Weill Cornell Medical College. He brings
to the Board more than 30 years of clinical and research experience
that includes pioneering development of treatments for women with
HER2-positive breast cancer and being actively involved in the
American Association for Cancer Research, where he has previously
served as President. He served as Chief, Hematology & Oncology
Division; Associate Director, Massachusetts General Hospital Cancer
Center from 2010 to 2012 and led the Vall d’Hebron Hospital in
Barcelona, a comprehensive cancer center with one of the largest
phase I programs for new cancer therapies in Europe, from 1996 to
2010. He has served as a Professor of Medicine at both Harvard
Medical School and Universitat Autonòma de Barcelona. Dr.
Baselga has been in leadership roles for a number of cancer
research organizations including Breast International Group and
Ludwig Institute for Cancer Research. He is also an elected member
of the National Academy of Medicine.
"José is an internationally-recognized physician scientist in
oncology with deep experience in teaching at leading academic
institutions, pioneering research for targeted cancer therapies and
treating patients, which he still continues today,”
said Giovanni Caforio, M.D., chairman and chief executive
officer, Bristol-Myers Squibb. “His close engagement with emerging
science across biotech and shared focus on patients brings valuable
contributions to helping us advance our strategy and pipeline of
transformational medicines.”
“With over 30 years of experience at the bench and in the
clinic, José brings a voice of innovation and practical,
patient-centric solutions to the Board,” said Vicki L. Sato, Ph.D.,
lead independent director, Bristol-Myers Squibb. “His knowledge
across cancer biology and drug development will bring tremendous
value to Bristol-Myers Squibb, and we look forward to working
together to advance new therapies for patients.”
“Bristol-Myers Squibb is a leader in harnessing the immune
system to fight cancer, and their diverse pipeline of targeted
therapies brings important hope for patients,” said Dr. Baselga. “I
am excited and honored to be appointed to the Board and I look
forward to working with Giovanni, his leadership team and the rest
of the Board.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, and YouTube.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180301006536/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorLaura Hortas,
609-252-4587laura.hortas@bms.comorInvestors:Tim Power;
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024